IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method for producing an oral pharmaceutical form with immediate disintegration and active ingredient release even in the mouth, [[by]] comprising vigorously mixing

- (a) an anionic active pharmaceutical ingredient with
- (b) a copolymer consisting of free-radical polymerized C₁ to C₄ esters of acrylic or methacrylic acid and further (meth)acrylate monomers which have functional tertiary amino groups, and
- (c) 5 to 50% by weight, based on (b), of a C_{12} to C_{22} carboxylic acid in the <u>a</u> melt, solidifying the mixture and grinding to an active ingredient-containing powder with an average particle size of 200 μ m or less, incorporating the powder into a water-soluble matrix of pharmaceutically customary excipients, with the proviso that not more than 3% by weight, based on the copolymer, of emulsifiers having an HLB of at least 14 may be present.

Claim 2 (Currently Amended): The method as claimed in claim 1, characterized in that wherein a twin-screw extruder is employed for the purpose of vigorous mixing in the melt.

Claim 3 (Currently Amended): The method as claimed in claim 1, or 2, characterized in that wherein extrusion takes place at temperatures in the range from 80 to 200°C

Claim 4 (Currently Amended): The method as claimed in one or more of claims 1 to 3, characterized in that Claim 1, wherein the incorporation of the powder into the water-soluble matrix takes place by compression, casting, granulation or freeze drying.

Claim 5 (Original): An active ingredient-containing powder with an average particle size of 200 µm or less, comprising

- (a) an anionic active pharmaceutical ingredient which is in the form of a solid solution and is incorporated into
- (b) a copolymer which consists of free-radical polymerized C₁ to C₄ esters of acrylic or methacrylic acid and further (meth)acrylate monomers which have functional tertiary amino groups, and
- (c) 5 to 50% by weight, based on (b), of a C₁₂ to C₂₂ carboxylic acid,
- (d) with the proviso that less than 3% by weight, based on the copolymer, or no emulsifier having an HLB of at least 14 is present.

Claim 6 (Currently Amended): The active ingredient-containing powder as claimed in claim 5, characterized in that wherein an anionic analgesic or an anionic antirheumatic or an anionic antibiotic is present as anionic active ingredient (a).

Claim 7 (Currently Amended): An active ingredient-containing powder as claimed in claim 5 or 6, characterized in that wherein the anionic active pharmaceutical ingredient (a) is at least one selected from the group consisting of acamprosate, aceclofenac, acemetacin, acetylcysteine, acetylsalicylic acid, acetyltyrosine, acipimox, acitretin, alanine, alendronic acid, amethopterin, amino acids, amoxicillin, ampicillin, ascorbic acid, atorvastatin, azidocillin, aztreonam, bacampicillin, baclofen, benazepril, bendamustine, benzylpenicillin,

bezafibrate, biotin, bornaprine, bumetanide, cabastine, canrenoic acid, carbamoylphenoxyacetic acid, carbidopa, carbimazole, carbocisteine, carisoprodol, cefaclor, cefadroxil, cefalexin, cefazolin, cefepime, cefetamet, cefixime, cefotaxime, cefotiam, cefoxitin, cefpodoxime, ceftazidime, ceftibuten, ceftriaxone, cefuroxime, cetirizine, chenodeoxycholic acid, chlorambucil, cidofovir, cilastatin, cilazapril, cinoxacin, ciprofloxacin, cisatracurium besilate, clavulanic acid, clodronic acid, clorazepate, cromoglicic acid, desmeninol, diclofenac, dicloxacillin, enoxacin, eprosartan, etacrynic acid, etidronic acid, etofylline, etomidate, felbinac, felodipine, fenofibrate, fexofenadine, flavoxate, fleroxacin, flucloxacillin, flufenamic acid, flumazenil, flupirtine, flurbiprofen, fluvastatin, fosfomycin, fosinopril, furosemide, fusidic acid, gabapentine, gemfibrozil, ibandronic acid, ibuprofen, iloprost, imidapril, imipenem, indomethacin, irinotecan, isradipine, ketoprofen, lercanidipine, levodopa, levofloxacin, liothyronine, lipoic acid, lisinopril, lodoxamide, lomefloxacin, lonazolac, loracarbef, loratadine, lovastatin, mefenamic acid, meropenem, mesalazine, metamizole, methotrexate, methyldopa, mezlocillin, moexipril, montelukast, moxifloxacin, mupirocin, naproxen, natamycin, nateglinide, nedocromil, nicotinic acid, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, norfloxacin, ofloxacin, olsalazine, orotic acid, oxacillin, pamidronic acid, pangamic acid, penicillamine, phenoxymethylpenicillin, pentosan polysulfate, perindopril, pethidine, pipemidic acid, piperacillin, pirenoxine, piretanide, probenecid, proglumide, propicillin, prostaglandins, quinapril, quinaprilate, ramipril, repaglinide, reserpine, risedronic acid, salicylic acid, sulfasalazine, spirapril, sulbactam, sulfasalazine, sultamicillin, tazarotene, tazobactam, telmisartan, tiagabine, tiaprofenic acid, tilidine, tiludronic acid, trandolapril, tranexamic acid, valproic acid, vigabatrine, vincamine, vinpocetine, zanamivir, zoledronic acid, zopiclone, and/or salts, isomers and/or combinations thereof are present as anionic active ingredient (a) salts thereof and isomers thereof.

Claim 8 (Currently Amended): The use of an active ingredient-containing powder as elaimed in one or more of claims 5 to 7 A method for producing an oral pharmaceutical form with immediate disintegration and active ingredient release even in the mouth, which causes no or only a slight bitter taste for at least 30 seconds after release comprising adding the active ingredient powder as claimed in Claim 5 to a pharmaceutical formulation.

Claim 9 (Currently Amended): The method as claimed in Claim 8 wherein the oral pharmaceutical form is use of the active ingredient containing powder as claimed in claim 8 for producing pharmaceutical forms such as compressed tablets or suckable tablets, freezedried tablets, cast tablets or pastilles, sachets, chewable tablets, powders for reconstitution, lozenges and/or liquid-filled lozenges.

Claim 10 (New): A medicament comprising the active ingredient-containing powder as claimed in Claim 5.

Claim 11 (New): A medicament prepared by the method as claimed in Claim 8.